The effect of a comprehensive, mail-based motivational program for patients receiving lipid-lowering therapy

Managed Care Interface

Volumn 16, Issue 3, 2003, Pages 35-40+62

  Truppo, Colleen ^a   Keller, Vivian A ^a   Reusch, Maria Teresa ^a   Pandya, Bhavik ^a   Bendich, David ^a  

^a BCBSNJ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POSTAL MAIL; PRACTICE GUIDELINE;

ADOLESCENT; ADULT; AGED; BLUE SHIELD; CHOLESTEROL, LDL; DISEASE MANAGEMENT; DRUG INDUSTRY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTERINSTITUTIONAL RELATIONS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MOTIVATION; NEW JERSEY; NEW YORK CITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTIONS, DRUG; PROGRAM EVALUATION;

EID: 0037344416     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Statistics you need to know. American Heart Association, May 9, 2002 (216.185.112.5/presenter.jhtml?identifier=107).
2. Miller NH, Hill M, Kottke T, et al: The multilevel compliance challenge: Recommendations for a call to action, a statement for healthcare professionals. American Heart Association, May 28, 2002 (216.185.112.5/presenter.jhtml?identifier=436).
3. 2002 Heart and Stroke Statistical Update. Dallas, American Heart Association, 2001.
4. Castelli WP: Epidemiology of coronary heart disease: The Framingham study. Am J Med 1984;76(2A):4-12.
5. Berenson GS, Srinivasan SR, Bao W, et al: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650-1656.
6. Andrade SE, Walker AM, Gottlieb LK, et al: Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Acad Med 1995;332:1125-1131.
7. Avorn J, Monette J, Lacour A, et al: Persistence of use of lipid-lowering medications: A cross-national study. JAMA 1998;279: 1458-1462.
8. West of Scotland Coronary Prevention Study Group: Compliance and adverse event withdrawal: Their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18: 1715-1724.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II.) JAMA 1993;269: 3015-3023.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
11. National Cholesterol Education Program: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. U.S Department of Health and Human Services publication No. (NIH) 01-3670, Bethesda, MD, National Institutes of Health, May, 2001.
12. Lee TH, Cleeman JI, Grundy SM, et al: Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000;283:94-98.